Safety and Efficacy of Oral Azacitidine (CC-486) Administered in Extended Treatment Schedules to Patients with Lower-Risk Myelod
PDF) Achievement of red blood cell transfusion independence in red blood cell transfusion-dependent patients with lower-risk non-del(5q) myelodysplastic syndromes correlates with serum erythropoietin levels
Expert Video - Are clinical trials an option in treatment failure or relapse in AML?
BARRY S SKIKNE, MD, Hematology KANSAS CITY, KS - NPI 1902992647
Dr. Barry Skikne, MD, Hematology Specialist - Westwood, KS | Sharecare
Barry SKIKNE | Celgene, Summit | Hematology | Research profile
The Iron Disorders Institute Guide to Anemia: Iron Disorders Institute, Garrison, Cheryl D.: 9781581822991: Amazon.com: Books
Long‐term survival with oral azacitidine for patients with acute myeloid leukemia in first remission after chemotherapy: updated results from the randomized, placebo‐controlled, phase 3 QUAZAR AML‐001 trial - Wei - American Journal
PHIL KLINE Obituary (2014) - Kansas City, MO - Kansas City Star
The University of Kansas Health System - Welcome to some of our newest physicians. From top left to bottom right: Natasha Ahmed, MD; Chantal Lucia Casadonte, MD; Alexander Chiu, MD; Haley Goucher,
Barry S. Skikne - CMO at TVAX Biomedical | The Org
The Iron Disorders Institute Guide to Anemia: Cumberland House Publishing: 9781581822991: Books - Amazon.ca
Dr. Barry S Skikne M.D., Hematologist (Blood Specialist) | Hematology in Kansas City, KS, 66160 | FindATopDoc.com
Who is at risk of treatment failure and relapse in AML? - YouTube
PDF) Improved differential diagnosis of anemia of chronic disease and iron deficiency anemia: A prospective multicenter evaluation of soluble transferrin receptor and the sTfR/log ferritin index | Barry Skikne and Paul Caldron -